The idea of preventing cancer and other diseases dates back to antiquity. Positive associations between environmental factors or behaviours and increased risk of cancer development have been alleged for at least 200 years. However, until the late twentieth century, little progress was made in understanding the underlying mechanisms of cancer development. The current thinking is that prevention is a highly feasible approach to cancer control. The question is, if prevention works, why does cancer still exist and pose a huge human and economic burden all over the world? The WHO (World Health Organization) predicts that by 2030 12 million of all deaths worldwide will be due to cancer (see the WHO Cancer Fact Sheet). Importantly, the WHO indicates that at least 30-40% of all cancer deaths are preventable 1 . This means, for example, that of the 7.4 million cancer deaths (or 13% of the total number of deaths worldwide) in 2004, 2.2-2.9 million could have been prevented.
Historically, research efforts have focused heavily on early detection and treatment, with little emphasis on environmental and lifestyle causes. Cancer prevention research has seemingly never been a major priority of health research until recently. And in spite of the renewed interest, only around 2% of the total budget of the National Cancer Institute (NCI) in the United States is directed towards cancer prevention and early detection (see the NCI's At A Glance Budget).
This Timeline article examines past discoveries and evaluates the cancer prevention research climate over time. The various ideas, driving forces and key players that shaped the field of cancer prevention research are also considered. The means by which scientific discoveries, concepts or techniques have shaped the development of cancer prevention research are discussed. The big questions that need to be addressed over the next few years in cancer prevention and cancer prevention research are introduced and the techniques that need to be improved or developed to answer these questions are presented.
Early observations
The importance of cancer prevention was realized early in human history, but the t i m E l i n E Cancer prevention researchthen and now
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Abstract | Throughout history, humankind has won the battle against deadly diseases, including small pox and polio, by defeating them through prevention. Cancer prevention is a global priority, but studying history suggests that the journey towards achieving this goal is difficult and full of detours and roadblocks. Epidemiology and clinical evidence clearly indicate that specific genetic, environmental and behavioural factors are associated with an increased risk for cancer development. What can we learn from the past that is applicable to the reality of successful cancer prevention?
Timeline | History of cancer prevention research Recognition of the dangers of tobacco use 4 Ionizing radiation (X-rays) discovered to induce tumours 9, 10 Absence of cervical cancer and high incidence of breast cancer in nuns is noted 3 Viruses shown to cause cancer in chickens 11 Occupationrelated scrotal cancer risk in chimney sweeps is observed 5 Vaginal cell smears (the Pap smear) shown to be able to reveal the presence of cervical cancer 43 • Cervical cancer is linked to a virus 46 • Tamoxifen found to prevent breast cancer in rats 40 Link between cigarette smoking and cancer is published 19, 22 US Surgeon General's report on smoking and lung cancer published 32 FOBT introduced to screen for colorectal cancer 74 Royal College of Physicians report on smoking and lung cancer 31 and risk of breast cancer published 39 CPS I on cigarette smoking and lung cancer death initiated 29, 30 Cancer induced in laboratory animals by application of coal tar 12 Pap smear introduced 44 Early version of mammogram presented 36 Asbestos exposure linked to risk of rare lung cancer, mesothelioma 33 First randomized controlled trial of periodic breast cancer screening with mammography initiated 37, 38 Chemoprophylaxis of carcinogenesis suggested by Lee Wattenberg 81 Term 'chemoprevention' is coined by Michael Sporn 82, 83 First colonoscopy of entire colon 75 Recognition of a relationship between age at menopause and risk of breast cancer 39 concept of research into the prevention of cancer was not recognized until much later. The association of an unhealthy diet with cancer was noted by the Roman physician Galen in 168 bc 2 . However, it was several hundred years before this observation had substantial company (Timeline). In 1713, Bernardino Ramazzini, an Italian doctor, reported the almost complete absence of cervical cancer and high incidence of breast cancer in nuns, and suggested that this might be related to their lifestyle, particularly their abstinence from sex 3 . During this period, tobacco use was first recognized as a health risk 4 , and exposure of chimney sweeps to soot was associated with a high risk of scrotal cancer 5 . In the nineteenth century, arsenic 6 , aromatic amines 7 and various other chemicals were added to the list of environmental cancer risk factors 8 . In 1902, X-rays were found to induce tumours 9, 10 , and in 1911 Peyton Rous showed that viruses can cause cancer in chickens 11 . The presence of carcinogens in coal tar was established in 1915 when laboratory animals exposed to this agent developed tumours 12 . Such observations directed most cancer prevention activities towards avoidance of industrial, occupational or environmental carcinogens 13 . Notably, these carcinogenic agents were identified by observational or epidemiological studies, and cancer prevention research in the eighteenth and nineteenth centuries was almost non-existent. Not everyone exposed to these carcinogens developed the disease, which made recommendations of lifestyle changes difficult, if not impossible.
Early twentieth century
The politics and key players in the United States. Because statistical evidence suggested that cancer death rates were increasing steadily in the late nineteenth and early twentieth centuries 14 , much of the contemporary research interest was focused on detecting and treating the disease. This investigative path was aided by the establishment of several cancer research associations and the dissemination of health information to the public. In 1907, the American Association for Cancer Research was established and held their first scientific meeting 15 , and in 1913 the Ladies' Home Journal published the first popular article about the warning signs for cancer 16 . Despite this, cancer was rarely publicized in the early twentieth century because it was so greatly feared. Although cancer research was becoming more of a priority, the importance of cancer prevention research was still not recognized. The idea that dietary changes, such as less meat and alcohol consumption, could prevent cancer was favoured by some researchers 17 . However, for much of the twentieth century, cancer prevention was not viewed separately from early detection and treatment.
In 1913, the American Society for the Control of Cancer (ASCC) was established by ten prominent physicians and five business leaders in New york, USA, and in 1944 it became the American Cancer Society (ACS; see Further information). The ASCC was a highly influential organization, the goal of which was to encourage Americans to seek early detection and treatment for cancer, and it was thought that cancer was curable if this practice was followed 18 . However, with the focus on patient care, physicians were able to do little except diagnose and try to treat the symptoms of cancer. early diagnosis and treatment was the standard policy and practice for cancer control for the first half of the twentieth century 18 , which probably contributed to the lack of organized research focusing on cancer prevention. In fact, the physician-dominated ASCC suggested that the idea of the diet causing or curing cancer was quackery and food faddism, and also proposed that changes to the diet would do nothing to prevent or treat cancer 17 . During the 1960s and 1970s, interest in environmental and lifestyle causes of cancer was revived and these factors were emphasized as potential health issues. even then, the idea of lifestyle changes was viewed by some scientists as a major threat to therapeutics as a CARET finds that β-carotene and retinol result in higher risk of lung cancer in smokers than placebo 103, 104, 108 48 HPV first identified in human cervical cancer 49 PCPT shows finasteride reduces the risk of prostate cancer 90 Celecoxib shown to prevent colon cancer polyps in individuals carrying the APC gene for familial adenomatous polyposis 95 • FDA approves raloxifene use for reducing the risk of invasive breast cancer • HPV clinical trial confirms effectiveness of vaccination against HPV 55, 58 • WHEL study indicates that diets high in vegetables, fruit and fibre and low in fat do not prevent breast cancer recurrence 115 • WINS shows that a low-fat diet may help prevent breast cancer recurrence in postmenopausal women 116, 117 • Results of WHI trial indicate a low-fat diet may reduce ovarian cancer incidence 122 SELECT shows that vitamin E and selenium do not prevent prostate cancer 112 US Surgeon General's report on Nutrition and Health indicates that the most important personal habits to affect health are smoking, alcohol consumption and diet 80 HPV recognized as a risk factor for cervical cancer 50, 51 Hybrid Capture II HPV DNA test approved by FDA as test used with Pap smear 52, 53 Second-hand smoke is classified as carcinogenic to humans 34 HPV clinical trial shows vaccine is effective against cervical cancer 54 Phase II trial shows that a combination of DFMO and sulindac prevents colon polyp recurrence 98 • STAR trial reveals raloxifene is as effective as tamoxifen at reducing the recurrence of invasive breast cancer 87 , supported by RUTH trial 89 • APC trial confirms effectiveness of celecoxib at preventing colon polyps but identifies increased adverse cardiovascular events 96 • FDA approves the vaccine Gardasil (Merck) to prevent HPV-induced cervical cancer 56,57 • The US Surgeon General's report on second-hand smoke is published 35 • WHI trial indicates no effect of low-fat diet on invasive breast cancer risk, and no effect of calcium and vitamin D on colorectal cancer risk 123, 124 MORE trial shows that raloxifene reduces the risk of breast cancer by 76% in postmenopausal women with osteoporosis 88 CPS II data demonstrate a decreased risk of colon cancer in people who take aspirin regularly 94 1978 1981 1982 1983 1987 1988 1991 1994 1996 1998 1999 2000 2002 2003 2006 2007 2008 2009 BRCA1 and BRCA2 genes identified as risk factors for breast cancer 41, 42 ATBC study finds increased lung cancer risk with β-carotene supplements in smokers and no effect of α-tocopherol 102 BCPT shows tamoxifen reduces breast cancer by 50% in high-risk women 86 FDA approves tamoxifen for prevention of breast cancer driving force in cancer control and prevention despite the fact that therapeutics had not increased cancer survival 17 . Several key events occurred during the first half of the twentieth century that eventually led to the emergence of a major emphasis on cancer prevention research during the second half of the century. In particular, the National Institute of Health (NIH) was established in 1930 and this was followed, in 1937, by the National Cancer Institute Act, signed by President Franklin D. Roosevelt, which authorized annual funding to support research related to the causes, diagnosis and treatment of cancer. In 1939, the NCI was formed and the first research into the association of smoking with lung cancer was initiated (see the About NCI web page). In 1955, the NCI formed the Cancer Chemotherapy National Service Center to focus on screening natural and synthetic compounds for their anticancer properties. Since its inception, the NCI has been a key driving force in cancer research including, most recently, cancer prevention research.
Throughout the early and mid twentieth century, the boundaries between science, industry and government were unclear. The American Health Foundation (also known as the Institute for Cancer Prevention) was founded in 1969 by ernst l. Wynder, whose work in the 1950s established the link between tobacco smoking and cancer 19 . The American Health Foundation (AHF; see Further information) was a not-for-profit private research organization devoted primarily to the prevention of chronic diseases, especially cancer. The establishment of an organization to focus on the prevention of chronic disease should have moved the field forward rapidly. However, the history of the AHF is overshadowed by controversy surrounding funding from tobacco companies and industry for research related to lifestyle causes of lung and other cancers (see the Integrity in Science web page on NonProfit Organizations Receiving Corporate Funding). The AHF eventually declared bankruptcy.
Other organizations founded with a focus on cancer prevention research in the United States included the American Institute for Cancer Research (AICR; see Further information), which was established in 1982. The AICR supports research into the role of the diet, physical activity and obesity in the prevention and treatment of cancer. This organization has worked with the World Cancer Research Fund International to publish two reports 20, 21 that, on the basis of an extensive review of the cancer research literature, offer their own series of recommendations for everyday cancer prevention.
Identification of cancer links and technological developments, 1900-1970.
Cancer research has been, and continues to be, driven by what are considered the most common and deadly cancers. The revival of interest in cancer prevention research in the 1980s up to the present day was certainly accelerated by the discovery of important associations between cancer development and environment, lifestyle and genetics. The advent of new technologies and other discoveries associated with detecting and treating lung, breast, cervical, skin and colon cancer throughout the 1950s, 1960s and 1970s all facilitated the identification of cancers and cancer risks much earlier than was previously possible.
Beginning in the 1950s, the relationship between smoking and lung cancer drove the evolution of epidemiology and clinical cancer research. In 1950, the link between cigarette smoking and cancer was confirmed 19, 22 . Notably, in 1954 the Hammond-Horn Study (USA) [23] [24] [25] and the British Doctors Study (UK) [26] [27] [28] further confirmed the link between smoking and lung cancer. The ACS initiated its first cancer prevention study (CPS I) in 1959, which also eventually linked cigarette smoking with early death from lung cancer 29, 30 . The 1962 Royal College of Physicians report 31 and the 1964 US Surgeon General's report 32 also linked smoking to lung cancer, and these two reports probably marked the beginning of a change in attitude towards lifestyle and environmental factors as causes of cancer, and the role of smoking in particular 17 . In 1960, asbestos exposure was linked to mesothelioma, a rare lung cancer 33 . This discovery further highlighted the need for genetic testing to determine the risk for certain inherited cancers, and might also have strengthened the idea of using surgery, such as mastectomy and oophorectomy, as a means of preventing cancer occurrence.
The discovery by George Papanicolaou in 1928 that vaginal cell smears can reveal the presence of cervical cancer 43, 44 was followed in 1943 by the introduction of the Papanicolaou (Pap) smear as a method of detecting carcinomas in the female genital tract. ernst Wynder later reported that barrier contraceptives were associated with a lower risk of cervical cancer, implicating a transmissive agent in the aetiology of cervical cancer 45 . Despite the early work of Peyton Rous, the viral theory of carcinogenesis was not taken seriously until the 1940s, although it only became a dominant theory in the 1970s 13 . In 1974, it was suggested that cervical cancer might be caused by a viral agent 46 . The hypothesis that certain cancers might be induced by viral infection led to a great deal of funding for the development of vaccines 47 . 56 , which protects against persistent infection by HPV16 and HPV18, which cause approximately 70% of cervical cancers worldwide 57 . Administering HPV vaccine to HPVnaive women and sexually active women may substantially reduce the incidence of HPV16-and HPV18-related cancers 58 .
Humans have been fascinated with sunlight since antiquity, and Hippocrates reportedly prescribed sunbathing (heliotherapy) for medical and psychological purposes. The existence of ultraviolet (UV) radiation in sunlight was well established by 1920, and interest in understanding the effect of UV radiation on humans was increasing 59 . Although early scientific research studies in animals 60 suggested that UV radiation might be dangerous or harmful, the primary opinion at that time was that sunlight had a positive influence on health. However, by the end of the twentieth century epidemiological evidence, supported by strong experimental evidence, suggested that solar UV irradiation is an important environmental carcinogen and a major aetiological factor in human skin cancer [61] [62] [63] [64] [65] [66] [67] [68] . Sunscreens alone seem to be imperfect in preventing skin cancers [69] [70] [71] [72] [73] , because an increased incidence of human skin cancer is apparent even with the application of sunscreen [71] [72] [73] . The most effective prevention seems to be moderation or avoidance of UV exposure.
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. This terminology was used mainly because they felt that to make firm scientific pronouncements about the association between diet and cancer was not yet possible because knowledge was at an interim stage similar to that for cigarettes 20 years previously 78 . On the basis of their review of the scientific literature, they concluded that various cancers occurring in different human populations seemed to correspond with differences in diet 78 . This idea was based on observations indicating that individuals who move from countries where the incidence of a particular cancer is low to countries with a high incidence of that cancer acquire the same cancer incidence as that of people native to the new country 79 . In general, they concluded that some types of diet and some dietary components (such as high-fat diets or the frequent consumption of salt-cured, salt-pickled and smoked foods) tend to increase the risk of cancer
, whereas others (such as low-fat diets or the frequent consumption of certain fruits and vegetables) tend to decrease it. On the basis of these results, they recommended a fat intake, especially of animal fat, of less than 30% of total energy intake 78 . Other recommendations included low sugar, salt and alcohol consumption, high consumption of fruit, vegetables and fibre, and to avoid being overweight 78 . Notably, the 1988 US Surgeon General's report on Nutrition and Health in the United States indicated that the three most important personal habits that influence health are smoking, alcohol consumption and diet 80 . 1990s to present -success of chemoprevention trials. The 1990s and early twenty-first century marked the beginning of a keen awareness of the effects of diet on health, and more interest in cancer prevention and cancer prevention research. In 1997, the NCI was reorganized to create the present-day Division of Cancer Prevention from the former Division of Cancer Prevention and Control (see the Division of Cancer Prevention History and mission web page). The mission of the Division of Cancer Prevention is to "plan, direct, implement, and monitor cancer research and training that is focused on early detection, cancer risk, chemoprevention, and supportive care. " The NIH currently defines cancer prevention as the reduction of the number of deaths from cancer through the reduction of cancer incidence, and suggests that cancer can be prevented by avoiding known risk factors such as carcinogens and smoking or by chemoprevention to reverse preneoplastic changes (see the NIH Cancer Prevention Overview). The term chemoprevention (initially "chemoprophylaxis of carcinogenesis" (ReF. 81)) was coined in 1976 (ReFs 82, 83) and is defined as the use of chemical agents, drugs and dietary supplements to prevent disease 84 . Several NCI-funded chemoprevention clinical trials were initiated or completed during this period, including the Breast Cancer Prevention Trial (BCPT; reported in 1998), the Study of Tamoxifen and Raloxifene trial (reported in 1999), which was a followup to the BCPT, and the Prostate Cancer Prevention Trial (reported in 2003). These three trials were considered successful in identifying drugs that could prevent prostate Box 1 | the effect of refrigeration on gastric cancer incidence
In Western countries the incidence of gastric cancer, once a very common cancer, fell dramatically between 1950 and 1990, seemingly without any specific intervention but corresponding to the increased availability of refrigeration 130, 131 . Since the turn of the century, new methods of processing and refrigeration have resulted in a huge variety in the types of food items available in developed countries. Gastric cancer is one of the most common cancers in developing countries and seems to be associated with diet, especially with a high intake of salted foods 132 . The use of refrigeration may be inversely correlated with the use of salting, with other methods of food preservation using salt (such as curing and smoking) and with the amount of dietary salt 20 . Increased refrigeration and decreased use of older food preservation methods have been attributed to the decline in deaths from stomach, liver and rectal cancers 133 . Long-term refrigerator use was shown to halve stomach cancer risk, and risk was high in subjects who as children did not have a means of cool storage of food 134 . The evaluation of cohort and case-control studies (1980-1990) revealed a consistently increased risk for stomach cancer when there was a non-centralized water supply (especially well water), high salt intake and a later availability of household refrigeration facilities 135 . The consensus view is that the decline in gastric cancer incidence in developed countries is attributable to improved food hygiene and increased availability of refrigeration facilities 136 , and perhaps also to the transition in food preservation methods from salting to refrigeration 132 . 85 . However, tamoxifen was associated with an increased risk for blood clots and endometrial cancer in postmenopausal women, but not premenopausal women. Updated results 86 confirmed the ability of tamoxifen to reduce the risk of breast cancer in high-risk women. In October 1998, on the basis of the initial results of the BCPT, the FDA approved the use of tamoxifen for the prevention of breast cancer in women at high risk of developing the disease. Initial results from the Study of Tamoxifen and Raloxifene trial 87 showed that raloxifene and tamoxifen were equally effective in reducing breast cancer risk in postmenopausal women who were at increased risk of the disease. The effectiveness of raloxifene was supported in two additional trials, the multiple Outcomes of Raloxifene evaluation in 1999 (ReF. 88) and the Raloxifene Use for The Heart 89 trials. On the basis of the results of these three trials, in September 2007 the FDA approved raloxifene for reducing the risk of invasive breast cancer in postmenopausal women. Results from the Prostate Cancer Prevention Trial showed that men who took finasteride (an anti-androgen agent) daily for 7 years had approximately 25% less risk of developing prostate cancer than men taking a placebo 90 . Initially, finasteride treatment was believed to be associated with a slightly increased risk for developing high-grade prostate tumours. However, new evidence suggests that this finding might have resulted from a reduction in prostate volume 91 and from facilitated diagnosis primarily because of increased biopsy sensitivity with finasteride 92 .
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Furthermore, on the basis of the results of radical prostatectomy, the rate of true highgrade disease might have been lower in the finasteride arm 93 .
Results from the ACS CPS II trial suggested that colon cancer risk could be decreased in people who took aspirin regularly 94 . The effect of celecoxib, a selective cyclooxygenase 2 (COX2) inhibitor, on colorectal polyps in patients with familial adenomatous polyposis was evaluated in a double-blind, placebo-controlled study. The results of this study indicated that 6 months of twice-daily treatment with 400 mg of celecoxib led to a significant reduction in the number of colorectal polyps 95 . These results were extended to a lower risk (sporadic adenoma) cohort in the 5-year Adenoma Prevention with Celecoxib trial 96 and the Prevention of Colorectal Sporadic Adenomatous Polyps trial 97 , but unfortunately in both trials the use of celecoxib was associated with an increased risk of adverse cardiovascular events. most recently, the results of a Phase III trial using low doses of the antiinflammatory sulindac and an investigational compound, difluoromethylornithine, showed significant efficacy for preventing colon polyp recurrence by 70% 98 . most notably, the results showed a 92% reduction in the recurrence of advanced adenomas. These results represent the first major clinical success with combination chemoprevention and are considered an important clinical advance 99 .
Diet-based intervention and the lows of dietary prevention trials. The idea that nutrition is an important factor in cancer causation is not new. Williams in 1908 (ReF. 100) observed that excessive eating and lack of exercise are predisposing factors for cancer, and in 1815 lambe 101 warned against the danger of excess consumption of food in general and meat in particular. early nutritionists demonstrated that many diseases could be dramatically cured not by removing a harmful toxin, but by correcting a nutrient deficiency 13 . In the early 1980s, Doll 77 reported that diet might be responsible for 10-70% of upper aerodigestive tract, oesophagus, stomach, large intestine and breast cancers. However, the relationship between diet and cancer is still a mystery, as cancer is a multifaceted disease and diet is a complex factor.
Since the 1990s the public interest in the effect of diet on health and its role in preventing cancer has expanded exponentially. The 5 A Day for Better Health programme in the United States was initiated in 1991 in a collaborative effort between the NCI and the Produce for Better Health Foundation.
Its purpose was to use every means of communication possible to encourage Americans to improve their eating habits to reduce the risk of diet-related cancers and other chronic diseases. The goal was to increase the average per capita consumption of fruit and vegetables in the United States to at least five servings per day. Unfortunately, on the basis of the data presented online by the Centers for Disease Control and Prevention (see their Fruit and Vegetable Consumption Data and Statistics web page), more Americans now eat either no fruit and vegetables or less than one serving (2.9% in 1996 compared with 4.4% in 2007) per day, and the number eating five servings per day has increased by only 0.3%. As of 1 january 2009, the 5 A Day programme has been replaced by the Fruits & Veggiesmore matters Tm strategy (see the Produce for Better Health Foundation web page). The goal of the replacement programme is essentially the same -to encourage Americans to want to eat more fruit and vegetables rather than to make them think that they should eat more fruit and vegetables.
Numerous dietary epidemiological observations and animal studies for a plethora of dietary factors from fruit and vegetables consistently suggest that one's diet provides protection against various cancers, but in general these findings have not yet been validated in randomized trials (FiG. 1) . In fact, the results of most dietary intervention clinical trials have been extremely disappointing. In the mid 1990s, diet-based cancer prevention suffered a major setback: the results of the β-Carotene Cancer Prevention Study showed that β-carotene was associated with an increased risk of lung cancer in smokers 102, 103 .
Results from the Alpha-Tocopherol, BetaCarotene Cancer Prevention (ATBC) study in Finland indicated that α-tocopherol had no effect on lung cancer incidence, but was associated with decreased prostate cancer risk 102 . Unexpectedly, a higher incidence of lung cancer was also observed in men receiving β-carotene than in those who did not. Concurrently, in the United States, the Beta Carotene and Retinol efficacy Trial (CAReT) was initiated and involved smokers, former smokers and workers exposed to asbestos. Its purpose was to examine the effect of daily β-carotene and retinol (vitamin A) supplementation on the incidence of lung cancer 104 . Similar to the ATBC study, the β-carotene group had a higher risk of lung cancer than the placebo group. The trial was stopped and follow-up continued for an additional 5 years 103 . Several follow-up studies were conducted. One study examined the incidence of lung cancer across subgroups of participants in the ATBC study, and the results supported the earlier findings. However, the results from this study also indicated that the β-carotene effect might be associated with heavier smoking and higher alcohol intake 105 . The statistical significance of the beneficial and adverse effects of supplemental α-tocopherol and β-carotene disappeared during post-intervention follow-up studies 106 . A later report indicated that plant foods have an important preventive influence in a population at high risk for lung cancer, but the effect is diminished with β-carotene supplements 107 . In another follow-up CAReT report, the adverse effects of β-carotene and vitamin A on lung cancer incidence in these high-risk individuals persisted after drug administration was stopped, but no longer reached statistical significance 108 . In contrast to earlier research suggesting that dietary supplementation with selenium and vitamin e may lower the risk of prostate cancer 102, 106, [109] [110] [111] , initial results from the largest ever prostate cancer prevention study, the Selenium and Vitamin e Cancer Prevention Trial, showed that these substances did not help prevent prostate cancer 112 . The data also showed a nonstatistically significant increase in the number of prostate cancer cases in men taking only vitamin e, but more analysis of the data is needed before a final conclusion can be drawn. Participants stopped taking supplements in October 2008 and will continue to be monitored for another 3 years.
Several epidemiology studies suggest that fibre can reduce cancer risk. However, a randomized trial to determine whether dietary supplementation with wheat-bran fibre could reduce the recurrence rate of colorectal adenomas showed no protective effect 113 . The Women's Healthy eating and living study was initiated in 2002 to determine the effectiveness of increased consumption of vegetables, fruit and fibre and decreased consumption of total fat at reducing additional breast cancer events and death in women who had been treated for early-stage invasive breast cancer within the previous 4 years 114 . The outcome measure was any invasive breast cancer event (recurrence or new primary) or death from any cause. Results indicated that the intervention group achieved and maintained statistically significant increased consumption of vegetables, fruit and fibre and decreased total fat consumption. Among survivors of earlystage breast cancer, adoption of a diet that was high in vegetables, fruit and fibre and low in fat did not reduce additional breast cancer events or mortality during a 7.3-year follow-up period 115 .
The findings seem to conflict with interim results from the Women's Intervention Nutrition Study, which showed that a low-fat diet can help to prevent breast cancer recurrence in postmenopausal women 116, 117 . As a direct comparison, a recent review reexamined the data from only the postmenopausal women from the two studies. The results of this review indicated that the evidence does not convincingly support the idea that changing dietary patterns will improve prognosis for most women with early-stage breast cancer. However, changes in diet seem to be important for some subgroups, and more investigations are needed 118 . The NIH announced the Women's Health Initiative in the spring of 1991, with the purpose of addressing three of the leading health problems for women: cardiovascular disease, breast and colon cancer, and osteoporosis 119 ; the programme was initiated in 1992 with a planned completion date of 2007. Women were enrolled in either a clinical trial or an observational study. For the clinical trial, the intervention for cancer included a low-fat eating pattern (proposed to prevent breast and colorectal cancer) or calcium and vitamin D supplementation (proposed to prevent colorectal cancer) 120 .
Results indicated that dietary fat intake was considerably lower in the dietary-modification intervention group than in the comparison group. Among postmenopausal women, a low-fat dietary pattern did not result in a statistically significant reduction of invasive breast cancer risk over an 8.1-year average follow-up period 121 . On the other hand, a low-fat dietary pattern was suggested to reduce the incidence of ovarian cancer among postmenopausal women 122 . later analyses suggested that a modest reduction in fat intake and an increase in fruit, vegetable and grain intake do not alter the risk of benign proliferative breast disease 123 . Finally, daily supplementation of calcium intake with vitamin D for 7 years had no effect on the incidence of colorectal cancer among postmenopausal women 124 .
Future strategies to prevent cancer On the basis of the almost total lack of success in the dietary-intervention clinical trials, one might wonder where we went wrong, and how we can move forwards. Some researchers suggest that we have moved from a period in which cancer causes were identified with very little understanding of the underlying mechanisms to a period in which the understanding of mechanisms has progressed extremely rapidly but has not yet contributed to effective strategies for cancer prevention 125 . Historically, the urgency to treat patients diagnosed with cancer understandably has been the dominant focus of cancer research. However, a broader view is necessary because, as with other diseases, prevention is likely to be a relatively straightforward and effective approach to control cancer. The NCI's current approach to cancer prevention is defined by the use of advanced tools and technologies, including those used in genomics, proteomics and metabolomics, to determine the molecular events associated with the early signs of cancer development (see its The Promise of Prevention and early Diagnosis web page). In 2003 the human genome was sequenced 126 , and the Cancer Genome Atlas Project is currently producing a list of all mutations associated with cancer. This list will be used to develop new strategies for preventing, diagnosing and treating cancer. molecular imaging technologies and supercomputer drug screening are just two of the new technologies that will be key in the development of effective anticancer agents with identified molecular targets.
A great deal of emphasis has been placed on the role of the diet in cancer risk. However, relying on epidemiological data to identify specific dietary agents obviously has not met with great success, especially in Figure 2 | effective routes to preventing cancer. Effective cancer prevention relies on identifying risk factors and understanding how, at the molecular level, these factors contribute to cancer initiation. A molecular understanding of the pathways and molecules involved in cancer initiation can be gained from studying patients with a known risk for a particular cancer type. Collation of this information can then be used to identify effective cancer strategies. HPV; human papillomavirus; UV, ultraviolet. 127 . These trials are intended to expedite the clinical evaluation of new molecules by allowing less restrictive requirements for manufacturing and toxicological assessment 128, 129 . Goals for Phase 0 trials include replication of preclinical mechanisms of action in a human intervention trial, characterization of initial pharmacokinetic and pharmacodynamic profiles, and evaluation of biodistribution patterns, based on imaging technologies. A Phase 0 trial should be conducted before the traditional Phase I dose-limiting toxicity trial, comprise only a limited number of subjects, have no therapeutic or diagnostic intent and be relatively short in duration. Success in a Phase 0 trial might permit an improved selection of effective compounds for further development. methods to identify compounds that have good bioavailability and are highly active earlier in the drug development cycle would offer clear advantages.
Prevention always relies on aetiology, and therefore education of the general public regarding risk factors associated with developing cancer is a must. The WHO has identified nine leading risk factors that could reduce cancer incidence (see the WHO Cancer Fact Sheet). On the basis of these, prevention strategies should include the avoidance of these risk factors, vaccination against HPV and hepatitis B virus, control of occupational hazards, and reduction of exposure to sunlight (FiG. 2) .
Summary and conclusions
Historically, the persistent focus on only early detection and treatment of cancer, with less emphasis on prevention, has not been very effective in eliminating this devastating disease. Clinical cancer prevention efforts are both incredibly important and exceedingly complex, and unfortunately these efforts have been vastly underemphasized. We have been unsuccessful in clinically confirming the results of epidemiological observational studies in large randomized trials. One might ask whether the lack of success of nutritional or other interventions is due to a lack of efficacy or to the weakness of rationale and study design. The latter is the most likely basis of our failure. In particular, the ATBC and CAReT trials were based on epidemiological studies linking high dietary intake and high serum levels of β-carotene or vitamin e to reduced risk of cancer (especially lung cancer). The justification for these trials was the assumption that these compounds act as antioxidants and therefore prevent DNA and cell damage by carcinogens. Notably, to our knowledge, few or no mechanistic or animal studies supported this rationale, and these epidemiological studies were a major setback in the cancer prevention field. By contrast, the studies with COX2 inhibitors were based on a plethora of mechanistic studies and animal data showing efficacy of these compounds in these models. Unfortunately, unforeseen cardiovascular toxicity accompanied prolonged and continued use of these inhibitors. However, small doses of COX2 inhibitors in high-risk individuals might still be worth the risk. Furthermore, some researchers suggest that the Selenium and Vitamin e Cancer Prevention Trial is an example of a study in which the wrong form of an anticancer agent (in this case selenomethionine versus high-selenium yeast that contain different forms of organically bound selenium in addition to selenomethionine) might have been used. These types of clinical trials are clear examples of our mistakes in designing and evaluating large-scale randomized studies. early detection, treatment and prevention would seem to constitute the complete strategy for cancer control (FiG. 3) . effectual future total anticancer strategies are crucial and need to meet specific criteria in order to succeed. These strategies must be practical and focus on high-risk populations, such as smokers, carriers of known genetic risk factors, specific ethnic groups, sunbathers and those in high-risk occupational or environmental positions. In this context, the use of screening (such as testing prostate serum antigen for prostate cancer, colonoscopy for colorectal cancer, mammography for breast cancer and Pap smear for cervical cancer) has the potential to greatly decrease cancer mortality and surely must be part of the complete strategy. The total strategy must also consider that cancer types vary in different countries and regions throughout the world. For example, Bangladesh is known to have high levels of arsenic-induced cancers, and both China and Korea have a high rate of smoking-and diet-inducedcancers. The complete strategy will probably evolve into more personalized prevention based on our different genetic backgrounds and varied sensitivity to environmental carcinogens. Genomics may be used more and more to identify high-risk individuals, and accurate end-point biomarker development will be crucial.
The complete cancer elimination strategy will require an allocation of additional resources and commitment by the scientific community, industry and government. We now have the tools for designing better large-scale studies based on 'omics' approaches, target selection and molecular therapies, which make more personalized strategies feasible. These newer strategies are supported by the positive results of targeted mechanistic drug trials such as the Prostate Cancer Prevention Trial (finasteride) and difluoromethylornithine and sulindac trials. Perhaps we can truly tackle cancer prevention with both holistic approaches (healthy living) and molecular approaches (selection of high-risk groups) as a new paradigm for pursuing cancer prevention research.
